Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm – OncLive
Dr. Welling on Incorporating Immunotherapy Into HCC ParadigmOncLiveTheodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agent… Continue reading
